Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: a validation using antipsychotic and glutamatergic agents.

Doyle OM, De Simoni S, Schwarz AJ, Brittain C, O'Daly OG, Williams SC, Mehta MA.

J Pharmacol Exp Ther. 2013 Apr;345(1):151-60. doi: 10.1124/jpet.112.201665. Epub 2013 Jan 31.

2.

Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study.

Deakin JF, Lees J, McKie S, Hallak JE, Williams SR, Dursun SM.

Arch Gen Psychiatry. 2008 Feb;65(2):154-64. doi: 10.1001/archgenpsychiatry.2007.37.

PMID:
18250253
3.

Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers.

De Simoni S, Schwarz AJ, O'Daly OG, Marquand AF, Brittain C, Gonzales C, Stephenson S, Williams SC, Mehta MA.

Neuroimage. 2013 Jan 1;64:75-90. doi: 10.1016/j.neuroimage.2012.09.037. Epub 2012 Sep 23.

PMID:
23009959
4.

Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine.

Gozzi A, Large CH, Schwarz A, Bertani S, Crestan V, Bifone A.

Neuropsychopharmacology. 2008 Jun;33(7):1690-703. Epub 2007 Sep 5.

5.

Modulatory effects of ketamine, risperidone and lamotrigine on resting brain perfusion in healthy human subjects.

Shcherbinin S, Doyle O, Zelaya FO, de Simoni S, Mehta MA, Schwarz AJ.

Psychopharmacology (Berl). 2015 Nov;232(21-22):4191-204. doi: 10.1007/s00213-015-4021-z. Epub 2015 Jul 31.

PMID:
26223493
6.

[Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].

Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L.

Encephale. 2001 Jan-Feb;27(1):53-9. Review. French.

PMID:
11294039
7.

Ketamine induces a robust whole-brain connectivity pattern that can be differentially modulated by drugs of different mechanism and clinical profile.

Joules R, Doyle OM, Schwarz AJ, O'Daly OG, Brammer M, Williams SC, Mehta MA.

Psychopharmacology (Berl). 2015 Nov;232(21-22):4205-18. doi: 10.1007/s00213-015-3951-9. Epub 2015 May 19.

8.

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH.

Arch Gen Psychiatry. 2000 Mar;57(3):270-6.

PMID:
10711913
9.

Ketamine-induced brain activation in awake female nonhuman primates: a translational functional imaging model.

Maltbie E, Gopinath K, Urushino N, Kempf D, Howell L.

Psychopharmacology (Berl). 2016 Mar;233(6):961-72. doi: 10.1007/s00213-015-4175-8. Epub 2015 Dec 10.

10.

Effects of ketamine on prefrontal and striatal regions in an overt verbal fluency task: a functional magnetic resonance imaging study.

Fu CH, Abel KM, Allin MP, Gasston D, Costafreda SG, Suckling J, Williams SC, McGuire PK.

Psychopharmacology (Berl). 2005 Nov;183(1):92-102. Epub 2005 Oct 22.

PMID:
16228196
11.

The effects of ketamine and risperidone on eye movement control in healthy volunteers.

Schmechtig A, Lees J, Perkins A, Altavilla A, Craig KJ, Dawson GR, William Deakin JF, Dourish CT, Evans LH, Koychev I, Weaver K, Smallman R, Walters J, Wilkinson LS, Morris R, Williams SC, Ettinger U.

Transl Psychiatry. 2013 Dec 10;3:e334. doi: 10.1038/tp.2013.109.

12.

Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation.

Duncan GE, Leipzig JN, Mailman RB, Lieberman JA.

Brain Res. 1998 Nov 23;812(1-2):65-75.

PMID:
9813244
13.

Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia.

Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M.

Biol Psychiatry. 2000 Oct 1;48(7):627-40.

PMID:
11032974
14.

Ketamine effects on brain function--simultaneous fMRI/EEG during a visual oddball task.

Musso F, Brinkmeyer J, Ecker D, London MK, Thieme G, Warbrick T, Wittsack HJ, Saleh A, Greb W, de Boer P, Winterer G.

Neuroimage. 2011 Sep 15;58(2):508-25. doi: 10.1016/j.neuroimage.2011.06.045. Epub 2011 Jun 29.

PMID:
21723949
15.

Mapping the central effects of chronic ketamine administration in an adolescent primate model by functional magnetic resonance imaging (fMRI).

Yu H, Li Q, Wang D, Shi L, Lu G, Sun L, Wang L, Zhu W, Mak YT, Wong N, Wang Y, Pan F, Yew DT.

Neurotoxicology. 2012 Jan;33(1):70-7. doi: 10.1016/j.neuro.2011.11.001. Epub 2011 Dec 2.

PMID:
22178134
16.

Nicotine and smoker status moderate brain electric and mood activation induced by ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist.

Knott V, McIntosh J, Millar A, Fisher D, Villeneuve C, Ilivitsky V, Horn E.

Pharmacol Biochem Behav. 2006 Sep;85(1):228-42. Epub 2006 Oct 3.

PMID:
17023037
17.
18.

Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine.

Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A.

Biol Psychiatry. 1997 Oct 15;42(8):664-8.

PMID:
9325559
19.

Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.

Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, Kovar KA.

Pharmacopsychiatry. 2005 Nov;38(6):301-11.

PMID:
16342002
20.

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS.

Arch Gen Psychiatry. 1994 Mar;51(3):199-214.

PMID:
8122957

Supplemental Content

Support Center